Pfizer Inc. to Advance Three Key Oncology Compounds into Phase 3 Trials in 2007, Company Tells Financial Analysts

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced that it is advancing key compounds through clinical development at a meeting with financial analysts today in connection with the American Society of Clinical Oncology annual meeting (ASCO) in Chicago. The company highlighted the following oncology compounds that are currently in Phase III trials as well as additional compounds expected to advance into Phase III trials in the next year: